QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the formation of a joint venture with Maccura Biotechnology Co., Ltd., a leading in vitro diagnostics (IVD) company in China. The joint venture, named MAQGEN plans to accelerate local adaptations, development and commercialization of the GeneReader NGS System in the rapidly growing clinical and clinical research markets in China. QIAGEN’s GeneReader NGS System is the world’s first complete Sample to Insight solution and makes the benefits of next-generation sequencing (NGS) accessible to any laboratory.
{iframe}http://www.military-technologies.net/2017/05/02/qiagen-partners-with-maccura-to-localize-and-commercialize-genereader-ngs-system-in-china-2/{/iframe}